All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported Terminated | 2012-004463-41 | - Ensaio clínico prospectivo, de fase IIa, multicêntrico, sem ocultação e não controlado para avaliar a eficacia e tolerabilidade do tratamento com eribulina como agente único de primeira linha em ... | 2015-12-02 | due-trials |
Listed as ongoing, but also has a completion date and reported results | 2014-004698-17 | A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic bre... | 2020-01-31 | bad-data |
Reported results | 2015-003892-31 | A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combinatio... | 2020-10-27 | due-trials |
Completed, but no date, and reported results Terminated | 2015-004828-66 | A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer an... | bad-data | |
Reported results | 2016-001888-36 | A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide bes... | 2021-02-28 | due-trials |
Ongoing | 2016-002676-27 | Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study | not-yet-due | |
Ongoing | 2016-002689-30 | Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer Ensayo fase II, abierto y multic... | not-yet-due | |
Ongoing | 2016-002892-80 | A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC) patients with homologous recombination deficiency treated with OLAparib single agent (NOBROLA study) Estudio de f... | not-yet-due | |
Ongoing | 2016-004513-27 | A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes Estudio de fase II de pembroliz... | not-yet-due | |
Not reported | 2017-002781-48 | INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN HORM... | 2023-02-02 | due-trials |
Ongoing | 2017-004323-72 | Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 ... | not-yet-due | |
Not reported Terminated | 2017-004324-30 | A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progressi... | 2021-03-31 | due-trials |
Ongoing | 2018-001213-32 | Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients – The OPHELIA Study – Eficacia de olaparib en c... | not-yet-due | |
Reported results | 2018-001702-28 | Neoadjuvant Letrozole and Palbociclib in patients with Stage II-IIIb breast cancer, HR (+) / HER2 (-) phenotype and Intermediate (18-25) or High (>25) Recurrence-Score by Oncotype-DX; analysis of RS a... | 2020-10-29 | due-trials |
Not reported | 2018-004648-44 | A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pretre... | 2023-11-10 | due-trials |
Listed as ongoing, but also has a completion date | 2019-001172-11 | A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy of ... | 2022-12-19 | bad-data |
Not reported | 2019-001503-20 | PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE... | 2023-12-07 | due-trials |
Not reported | 2019-001739-29 | A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer with ... | 2023-04-04 | due-trials |
Ongoing | 2019-003096-20 | A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer Ensayo de fase II randomiz... | not-yet-due | |
Other | 2020-000397-18 | A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI Studio ... | not-yet-due | |
Ongoing | 2020-001160-28 | A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneum... | not-yet-due | |
Other | 2020-001648-24 | A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as fi... | not-yet-due | |
Ongoing | 2020-003205-66 | Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Estrategia sin quimioterapia basada en la repuesta patol... | not-yet-due | |
Ongoing | 2022-001397-61 | Multicenter, Open-label,Single arm,Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative Breast Cancer.–The PRIMED Study– Ensayo clínico mul... | not-yet-due | |
Ongoing | 2022-001398-30 | PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 MONO... | not-yet-due | |
Ongoing | 2022-002616-24 | A proof of concept study to evaluate treatments’ efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative early breast cancer population. Estudio preliminar de efica... | not-yet-due |